AbbVie Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: AbbVie Inc. vs. Amphastar Pharmaceuticals, Inc.

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, AbbVie Inc. and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A cost management. AbbVie, a global biopharmaceutical leader, has seen its SG&A expenses grow by approximately 66% over this period, peaking in 2022. In contrast, Amphastar, a specialty pharmaceutical company, has maintained a more modest increase of around 99%, reflecting a more controlled expansion strategy.

While AbbVie's expenses surged, particularly in 2020 and 2021, Amphastar's costs remained relatively stable, with a notable increase in 2023. This data suggests that Amphastar may be more efficient in managing its SG&A costs relative to its size. Investors and industry analysts should consider these trends when evaluating the operational efficiency and strategic priorities of these companies.